Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sandoz Group AG (SDZ.SW)
Rotkreuz, CH
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.43% | +1.55% | +4.89% | -3.56% | +15.66% | +14.65% | +57.01% | +122.37% | +122.37% | +122.37% | +122.37% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | +1 |
| Buy | 5 | 0 |
| Hold | 7 | -1 |
| Sell | 1 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+27.3% ★ Q4'25: +178.1% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%— Q4'25: +926.7% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+18.2% Q4'25: +8.3% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+15.4% ★ Q4'25: +17.4% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.2% ★ Q4'25: +23.6% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.7% Q4'25: +1.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.18× Q4'25: 1.38× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 14 Rev. Ana. 13 EPS Ana. |
Dec 2027 15 Rev. Ana. 13 EPS Ana. |
Dec 2028 13 Rev. Ana. 9 EPS Ana. |
Dec 2029 12 Rev. Ana. 3 EPS Ana. |
Dec 2030 6 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
9.98B
est: 11.28B (-11.6%)
|
9.12B
est: 10.39B (-12.2%)
|
11.61B
est: 11.10B (+4.6%)
|
11.92B
11.81B – 12.02B
+7.4% YoY
|
12.52B
11.99B – 12.78B
+5.0% YoY
|
13.12B
12.78B – 13.31B
+4.8% YoY
|
13.87B
13.51B – 14.07B
+5.7% YoY
|
14.53B
14.15B – 14.74B
+4.7% YoY
|
| EBITDA |
857.00M
est: 1.54B (-44.3%)
|
667.55M
est: 1.42B (-52.9%)
|
1.79B
est: 1.51B (+18.1%)
|
1.62B
1.61B – 1.64B
+7.4% YoY
|
1.71B
1.63B – 1.74B
+5.0% YoY
|
1.79B
1.74B – 1.81B
+4.8% YoY
|
1.89B
1.84B – 1.92B
+5.7% YoY
|
1.98B
1.93B – 2.01B
+4.7% YoY
|
| EBIT |
332.00M
est: 1.10B (-69.9%)
|
225.45M
est: 1.02B (-77.8%)
|
1.79B
est: 1.09B (+64.6%)
|
1.17B
1.15B – 1.18B
+7.4% YoY
|
1.22B
1.17B – 1.25B
+5.0% YoY
|
1.28B
1.25B – 1.30B
+4.8% YoY
|
1.36B
1.32B – 1.38B
+5.7% YoY
|
1.42B
1.38B – 1.44B
+4.7% YoY
|
| Net Income |
77.00M
est: -8.93M (+962.4%)
|
1.00M
est: 1.19B (-99.9%)
|
957.48M
est: 1.54B (-37.7%)
|
1.75B
1.67B – 2.16B
+14.0% YoY
|
2.16B
1.84B – 2.46B
+23.4% YoY
|
2.05B
1.74B – 2.37B
-5.2% YoY
|
2.45B
2.37B – 2.50B
+19.5% YoY
|
2.66B
2.57B – 2.71B
+8.4% YoY
|
| SGA |
2.39B
est: 2.67B (-10.5%)
|
2.43B
est: 2.46B (-1.0%)
|
2.65B
est: 2.63B (+0.9%)
|
2.82B
2.79B – 2.84B
+7.4% YoY
|
2.96B
2.84B – 3.02B
+5.0% YoY
|
3.10B
3.02B – 3.15B
+4.8% YoY
|
3.28B
3.19B – 3.33B
+5.7% YoY
|
3.44B
3.35B – 3.49B
+4.7% YoY
|
| EPS |
0.18
est: -0.02 (+967.0%)
|
—
est: 2.75 (-100.0%)
|
2.22
est: 3.35 (-33.7%)
|
4.02
3.83 – 4.93
+20.0% YoY
|
4.56
4.21 – 5.63
+13.4% YoY
|
5.10
3.98 – 5.42
+11.9% YoY
|
5.61
5.42 – 5.72
+10.2% YoY
|
6.09
5.88 – 6.20
+8.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-15 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Richard Saynor | Chief Executive Officer | 4M | male |
| Remco J. Steenbergen | Chief Financial Officer | 2M | male |
| Claire D'Abreu-Hayling | Chief Scientific Officer & President of Generics Development | — | female |
| Craig Marks | Head of Investor Relations | — | male |
| Glenn A. Gerecke | Chief Manufacturing & Supply Officer and President of Generics Manufacturing and Supply | — | — |
| Ingrid Sollerer | General Counsel & Chief Compliance Officer | — | female |
| Keren Haruvi | President of North America | — | female |
| Rebecca Guntern | Chief Commercial Officer | — | female |
| Simon Wolfgang Hartmut Goeller | Chief Transformation & Growth Officer | — | male |
| Asaf Gal | Chief Technology Officer | — | male |
| Tripti Jha | Chief People Officer | — | female |
| Christophe Delenta | President of Europe | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SDZ.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
